EP1345914A1 — Therapeutic compounds
Assigned to AstraZeneca AB · Expires 2003-09-24 · 23y expired
What this patent protects
Compounds of the formula (I) for use as an estrogen receptor -β-selective ligand are described wherein: X is O or S; and R?1, R3 R6¿ are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteo…
USPTO Abstract
Compounds of the formula (I) for use as an estrogen receptor -β-selective ligand are described wherein: X is O or S; and R?1, R3 R6¿ are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.